PIK3CA and head and neck squamous cell carcinoma: To our knowledge, this is the first study demonstrating the additive or synergistic effects of buparlisib and cetuximab in a clinical trial based on preclinical PDX data, which can significantly contribute to the clinical development of PI3K inhibitors in R/M SCCHN patients.